OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
Box 7088
Halmstad 300 07
Sweden
Storgatan 36
Halmstad 302 43
Sweden
Sebastien Bollue joined the Company in 2016, first in the role as Commercial Operations Manager and then as Director of Commercial Operations. He is responsible for the supply chain and leading day-to-day commercial activities, but also coordinates distribution, marketing and clinical evaluations.
Jennie Kardell joined Redsense as CFO in March 2023. Jennie has broad financial skills and solid experience of accounting, process development, international establishments, IPO's and business acquisitions from a number of leading roles, including as interim CFO. She previously was a partner at Oresunds Redovisning, where she, led the integration following Ludvig & Co's acquisition of the company in 2021. Jennie Kardell holds a Bachelor of Science in Business and Economics from Uppsala University and is an SRF Certified Accounting Consultant. In addition, she is current President of SRF Konsulterna, Sodra Kretsen. Since end of May 2024, Jennie is acting CEO of Redsense Medical AB
Ann-Marie Eriksson joined Redsense Medical in January 2020 as new CTO. Ann-Marie Eriksson holds a Master of Science in Electrical Engineering with specialization in signal processing and telecommunications from the Chalmers University of Technology. Her most recent position was at the Halmstad branch of Etteplan Sweden AB, Swedish subsidiary of the international engineering group Etteplan, where she lead the team successfully as Department Manager, Area Manager and Teamleader. She has solid experience of project management and quality systems management, with particular expertise in medical devices.
Eva Walde holds a Master of Science in Business and Economics from the School of Economics in Gothenburg. She has over 30 years of experience in senior positions in pharmaceuticals, medical devices, diagnostics and biotechnology industries, mainly in marketing and sales. Most recently, Eva was VP Global Marketing at Olink Proteomics AB. Previously, she has held roles as VP Commercial Operations, International Region at Phadia/ThermoFisher Scientific and Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB. Eva is a board member of Sedana Medical AB since 2018, Senzime AB since 2020 and Scale Up Life Science AB since 2023.
Malin Almgren has a master's degree in Biochemistry and a PhD in medical research and has over 20 years of experience in the research field. She has worked for over two decades at esteemed institutions such as Karolinska Institutet and UCSD, gaining expertise in various fields like genetics/epigenetics, immunology, neuroscience, and oncology. Her experience also includes working on clinical trials and collaborations with the industry. Aside from her scientific expertise, Malin has also developed a second career within finance. She has worked at a Swedish asset management firm, Tundra Fonder, with focus on sustainable investments. Additionally, she has worked as a financial advisor for M&A transactions in the healthcare sector at Experia Corporate Finance Advisors. Currently, Malin is CEO of Schain Research AB, where she uses her knowledge of both science and economics to drive the company's success. She is also a board member at Experia Nordic Oy.
Susanne Olauson is currently the CEO of Odinwell AB. She has twenty years of sales experience in the pharmaceutical industry, the medical technology industry and life science. Has held positions as VP Commercial Operations, European Congress Manager, Director Sales & Marketing development, product specialist and product manager in medical technology and pharma.
Lena Oswald has a strategic profile with a focus on building and developing companies commercially and internationally. Thirty years of experience as advisor at a high level in all types of companies. Lena has knowledge, experience and ability to position companies, brands, develop assortments and sales channels (subsidiaries, distributors) and markets globally. She is specialized in the connection between business strategy, organization and people. Lena combines a holistic view, from the outside in perspective, with implementation and action. Executive Chairman of Bolon from 2017, a family-owned Swedish floor design company with international operations. Board member of Form Us With Love from 2022, an industrial design company with venture/incubator operations. Chairman of InterPares, a management consulting company that she has been active in since 2014.
Kopmansgatan 41
Halmstad 3002 32
Sweden
Redsense Medical has developed the Redsense System, an innovation used for monitoring hemodialysis treatment and alarming in the event of blood leakage. The system consists of a patented fiber optic sensor which is embedded in a disposable patch designed for either a venous needle or central venous catheter, which is then connected to an alarm unit and is triggered when the sensor comes into contact with blood so one can address the issue immediately and stop the blood flow. From the very start, development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The system is the only blood leakage system on the market that is both CE marked and FDA cleared for sales in the USA. In more than 15 years of clinical use, patients and nurses have felt safer when using the Redsense alarm system to detect VND. Redsense is proud to count the 5 largest dialysis providers in the USA among users of the Redsense blood leakage system. The US department of Veteran Affairs even mandates the use of Redsense System for hemodialysis treatments. Most recently, Redsense has engaged in R&D into the Redsense Clamp, a device that works directly with the Redsense alarm that, when triggered, automatically closes the venous bloodline, preventing additional blood loss. The Redsense Clamp is expected to be launched in 2024.
Redsense Medical AB corporate headquarter is located in Halmstad, Sweden. For the US sales and marketing operations, Redsense has a US subsidiary. For sales in Europe and Canada, Redsense mostly work with distribution partners. Redsense outsource activities related to manufacturing to well selected and established supply partners in Sweden and Asia.